Drug Repurposing Compound Library
Cat. No. : | CS-L035 | (4313 compounds) |
---|
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE Drug Repurposing Compound Library contains 4313 approved drugs and passing phase Ⅰclinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties.
Size (Pre-dissolved DMSO or Solid) | Stock | Price |
---|---|---|
30 μL/well (10 mM solution) | In-stock | Get quote |
50 μL/well (10 mM solution) | In-stock | Get quote |
100 μL/well (10 mM solution) | In-stock | Get quote |
250 μL/well (10 mM solution) | In-stock | Get quote |
Data Sheet
Description & Advantages
Composition
Contents
Formulation: | A collection of 4313 bioactive compounds supplied as pre-dissolved Solutions or Solid |
---|---|
Container: | 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode |
Storage: | -80°C |
Shipping: | Blue ice |
Customize Your Library
You can select:- Specific Compounds
- Quantities
- Plate map
- Concentration
- Format (Solid or DMSO Solution)
Please contact us at sales@chemscene.com